Matrix metalloproteases: Underutilized targets for drug delivery

被引:117
作者
Vartak, Deepali G.
Gemeinhart, Richard A.
机构
[1] Univ Illinois, Coll Pharm, Dept Biopharmaceut Sci, Chicago, IL 60612 USA
[2] Univ Illinois, Dept Bioengn, Chicago, IL 60612 USA
关键词
drug delivery; drug targeting; matrix metalloprotease (MMP); prodrug; drug activation;
D O I
10.1080/10611860600968967
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pathophysiological molecules in the extracellular environment offer excellent targets that can be exploited for designing drug targeting systems. Matrix metalloproteases (MMPs) are a family of extracellular proteolytic enzymes that are characterized by their overexpression or overactivity in several pathologies. Over the last two decades, the MMP literature reveals heightened interest in the research involving MMP biology, pathology and targeting. This review describes various strategies that have been designed to utilize MMPs for targeting therapeutic entities. Key factors that need to be considered in the successful design of such systems have been identified based on the analyses of these strategies. Development of targeted drug delivery using MMPs has been steadily pursued; however, drug delivery efforts using these targets need to be intensified and focused to realize the clinical application of the fast developing fundamental MMP research.
引用
收藏
页码:1 / 20
页数:20
相关论文
共 171 条
[41]   Matrix metalloproteinases in cerebrovascular diseases [J].
Fatar, M ;
Stroick, M ;
Griebe, M ;
Hennerici, M .
CEREBROVASCULAR DISEASES, 2005, 20 (03) :141-151
[42]   Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects [J].
Fingleton, B .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2003, 7 (03) :385-397
[43]  
Fini M.E., 1992, ACTA OPHTHALMOL S, P26
[44]   Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis [J].
Foda, HD ;
Zucker, S .
DRUG DISCOVERY TODAY, 2001, 6 (09) :478-482
[45]  
FRIDMAN R, 1995, CANCER RES, V55, P2548
[46]   INCREASED EXPRESSION OF MATRIX METALLOPROTEINASES AND MATRIX-DEGRADING ACTIVITY IN VULNERABLE REGIONS OF HUMAN ATHEROSCLEROTIC PLAQUES [J].
GALIS, ZS ;
SUKHOVA, GK ;
LARK, MW ;
LIBBY, P .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (06) :2493-2503
[47]   Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling [J].
Gálvez, BG ;
Matías-Román, S ;
Albar, JP ;
Sánchez-Madrid, F ;
Arroyo, AG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (40) :37491-37500
[48]   Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug [J].
Gerspach, J ;
Müller, D ;
Münkel, S ;
Selchow, O ;
Nemeth, J ;
Noack, M ;
Petrul, H ;
Menrad, A ;
Wajant, H ;
Pfizenmaier, K .
CELL DEATH AND DIFFERENTIATION, 2006, 13 (02) :273-284
[49]  
GLAZIER A, 1997, Patent No. 5659061
[50]   HUMAN 72-KILODALTON TYPE-IV COLLAGENASE FORMS A COMPLEX WITH A TISSUE INHIBITOR OF METALLOPROTEASES DESIGNATED TIMP-2 [J].
GOLDBERG, GI ;
MARMER, BL ;
GRANT, GA ;
EISEN, AZ ;
WILHELM, S ;
HE, CS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (21) :8207-8211